Lynparza, First In Its Class Of Cancer Drugs, Offers Surprisingly Broad Activity

So far, the studies demonstrate that Lynparza has activity in cancer patients with and without inherited BRCA mutations. When combined with DNA-damaging chemotherapy or new targeted drugs, PARP inhibitors may be useful in treating a wider range of malignancies than was previously realized.